Who are RC148 plus Carboplatin and Paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DURVALUMAB, AVELUMAB, Pf-06823859, Avelumab first-line maintenance, AB, Pf-06865571.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rc148-plus-carboplatin-and-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

RC148 plus Carboplatin and Paclitaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RC148 plus Carboplatin and Paclitaxel (RC148 plus Carboplatin and Paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor. Area: Oncology.

phase 3 PD-L1 inhibitor PD-L1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

RC148 plus Carboplatin and Paclitaxel (RC148 plus Carboplatin and Paclitaxel) — RemeGen Co., Ltd.. RC148 is a PD-L1 inhibitor combined with standard chemotherapy (carboplatin and paclitaxel) to enhance anti-tumor immune response while providing cytotoxic chemotherapy.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RC148 plus Carboplatin and Paclitaxel TARGET	RC148 plus Carboplatin and Paclitaxel	RemeGen Co., Ltd.	phase 3	PD-L1 inhibitor	PD-L1
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
AVELUMAB	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
Pf-06823859	pf-06823859	Pfizer	marketed	Monoclonal Antibody	PD-1/PD-L1
Avelumab first-line maintenance	Avelumab first-line maintenance	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	PD-L1 inhibitor	PD-L1
AB	AB	GlaxoSmithKline	marketed	PD-L1 inhibitor	PD-L1
Pf-06865571	pf-06865571	Pfizer	marketed	Monoclonal antibody	PD-1/PD-L1 pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor class)

Biocad · 13 drugs in this class
Shanghai Henlius Biotech · 8 drugs in this class
Celltrion · 5 drugs in this class
Mabwell (Shanghai) Bioscience Co., Ltd. · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · 2 drugs in this class
Innovent Biologics (Suzhou) Co. Ltd. · 2 drugs in this class
Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
Shanghai Hengrui Pharmaceutical Co., Ltd. · 2 drugs in this class
CStone Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RC148 plus Carboplatin and Paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/rc148-plus-carboplatin-and-paclitaxel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab